From Our Readers

From Our Readers

You Make the Call

Reader Responses: Is JAK2 positivity clinically significant in this 28-year-old patient with Budd-Chiari syndrome?

Here’s how readers responded to a You Make the Call question about the clinical significance of JAK2 positivity in a patient with Budd-Chiari syndrome. Disclaimer:...

The New ACCME Standards: A Pendulum Swung Too Far?

In this edition, Judith Kleinerman, MD, talks about the implications of the Accreditation Council for Continuing Medical Education’s (ACCME’s) new Standards for Integrity and...
You Make the Call

Reader Responses: How would you manage this patient with T-cell large granular lymphocytic leukemia?

Here’s how readers responded to a You Make the Call question about management of a patient with T-cell large granular lymphocytic leukemia. Disclaimer: ASH does...

Marrow or Peripheral Blood for Allogeneic Transplant: Are We Ignoring the Data?

Here, Jennifer Saultz, DO, and Eneida Nemecek, MD, MBA, reflect on the debate over the optimal graft source for allogeneic hematopoietic cell transplantation, in...

Singing the Blues for Blue Top Tubes

Here, Mark A. Crowther, MD, and Steven L. Allen, MD, discuss the recent shortages of blue top tubes and how hematologists can “choose wisely”...
You Make the Call

Reader Responses: How would you approach diathesis in a 65-year-old woman with newly diagnosed...

Here’s how readers responded to a You Make the Call question about a bleeding diathesis in a 65-year-old woman with newly diagnosed breast cancer. Disclaimer: ASH...

Masking, Vaccination, and Research Needed to Protect Our Most Vulnerable Against COVID-19

This article is republished from a President’s Column that originally appeared in the July/August 2021 issue of The Hematologist. In mid-May, the Centers for Disease...
You Make the Call

Reader Responses: How would you treat this 38-year-old patient with sickle cell trait and end-stage...

Here’s how readers responded to a You Make the Call question about treatment for a patient with sickle cell trait and end-stage renal disease. Disclaimer:...
You Make the Call

Reader Responses: Should a mostly asymptomatic patient with amyloidosis receive systemic therapy?

Here’s how readers responded to a You Make the Call question about whether a mostly asymptomatic patient with amyloidosis should receive systemic therapy. Disclaimer: ASH...

How Can the Myeloma Community Reduce Disparities in Care?

In our March 2021 issue, we reported on findings from a review article examining disparities in outcomes among patients with multiple myeloma (MM), in...
Advertisement

Current Issue

September 2021 Volume 7 Issue 11

This issue discusses fertility preservation for young patients with cancer, reviews treatment options for primary immune thrombocytopenia, and more.

Block title